JCR Pharmaceuticals Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Second Quarter of Fiscal Year 2019 and Year Ending March 31, 2019
July 25, 2018
Share
JCR Pharmaceuticals Co., Ltd. announced consolidated earnings results for the first quarter ended June 30, 2018. For the quarter, the company reported Net Sales were JPY 4,677 million against JPY 4,386 million a year ago. Operating income was JPY 539 million against JPY 609 million a year ago. Ordinary income was JPY 574 million against JPY 628 million a year ago. Profit before income taxes was JPY 410 million against JPY 634 million a year ago. Profit was JPY 282 million against JPY 495 million a year ago. Profit attributable to owners of parent was JPY 282 million against JPY 495 million a year ago. Diluted income per share was JPY 9.14 against JPY 15.61 a year ago.
The company also provided earnings guidance for the second quarter of fiscal year 2019 and year ending March 31, 2019. For the second quarter, the company expects net sales of JPY 9,400 million. Operating income is expected to be JPY 820 million. Ordinary income is expected to be JPY 870 million. Profit attributable to the owners of the parent is expected to be JPY 650 million. Net income per share is expected to be JPY 21.13 per share.
For the year, the company expects net sales of JPY 21,900 million. Operating income is expected to be JPY 4,290 million. Ordinary income is expected to be JPY 4,360 million. Profit attributable to the owners of the parent is expected to be JPY 3,200 million. Net income per share is expected to be JPY 104.05 per share.
JCR Pharmaceuticals Co., Ltd. is a Japan-based company primarily engaged in the pharmaceutical business, as well as the medical and research equipment business. The Company operates in two segments. The Pharmaceutical segment engages in the research, production, purchase and sale of medical drugs and pharmaceutical raw materials. The Medical and Research Equipment segment engages in the purchase and sale of the medical and research equipment.
JCR Pharmaceuticals Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Second Quarter of Fiscal Year 2019 and Year Ending March 31, 2019